Waverly Advisors’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Waverly Advisors’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$558K	Buy	3,524 +805	+30%	+$109K	﹤0.01%	1125
2026 Q1	$347K	Sell	2,719 -203	-7%	-$25.3K	﹤0.01%	1241
2025 Q4	$356K	Buy	+2,922	New	+$335K	﹤0.01%	1140
2023 Q3	–	Sell	-6,333	Closed	-$527K	–	415
2023 Q2	$527K	Sell	6,333 -618	-9%	-$51.7K	0.02%	240
2023 Q1	$530K	Buy	+6,951	New	+$577K	0.03%	190

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

Waverly Advisors's XBI Position: Q2 2026 in Review

Waverly Advisors increased its State Street SPDR S&P Biotech ETF (XBI) stake by 30% in Q2 2026, buying an estimated $109K and bringing the position to 3,524 shares worth $558K. The position accounts for ﹤0.01% of the portfolio, ranked #1125.

Waverly Advisors first reported a position in XBI in Q1 2023 and has held it in 5 quarters since. 936 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

Waverly Advisors held 3,524 shares of State Street SPDR S&P Biotech ETF worth $558K as of Q2 2026.
Waverly Advisors bought 805 State Street SPDR S&P Biotech ETF shares in Q2 2026, an estimated $109K.
State Street SPDR S&P Biotech ETF made up ﹤0.01% of Waverly Advisors's portfolio in Q2 2026, its #1125 holding.
Waverly Advisors first reported a position in State Street SPDR S&P Biotech ETF in Q1 2023 and has held it in 5 quarters since.
936 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Waverly Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.